Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07454837 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 41 → 44 locationsv9
  2. Trial sites expanded: 35 → 41 locations
    • Secondary endpoints revised (18)
    v8
  3. Secondary endpoints: 13 to 18v7
  4. Trial sites expanded: 22 → 35 locationsv6
  5. Trial sites expanded: 13 → 22 locations
    • Study title shortened, about 2 words
    v5
  6. Trial sites expanded: 10 → 13 locationsv4
  7. Trial sites expanded: 7 → 10 locationsv3
  8. Study sites: 5 to 7v2
  9. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).
Trial Details
NCT Number NCT07454837
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Chronic Hepatitis D
Related terms Hepatitis D, Chronic
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov